Payment & Shipping Terms:
|Cas No.:||167933-07-5||Product NameEszopiclone:||Flibanserin|
|Usage:||Pharmaceutical Raw Material||Appearance:||White Powder|
|Assay:||99% Flibanserin||Grade:||Pharmaceutical Grade|
|Storage:||Cool Dried Storage||Application:||Pharmaceutical Raw Intermediates|
Product name: Flibanserin powder
Another name: Bimt 17
Chemical formula: C20H21F3N4O
Molecular weight: 426.86
CAS number: 167933-07-5
Appearance: White Crystal Powder
Purity (HPLC): 99.0%
Flibanserin, is a medication approved for the treatment of pre-menopausal women withhypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three. The certainty of the estimate is low. The side effects of dizziness, sleepiness, and nausea occur about three to four times more often.
Flibanserin is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with sexual problems. Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain. This in return seemingly has a positive effect on a woman's sexual craving who was otherwise lacking in this area. The benefits of it being Non-Hormonal are that it will not have the problems associated with other hormonal treatments such as a negative altered mood among other issues.
Flibanserin, a drug used to increase female libido, reduces the suppression of sexually active serotonin to increase dopamine levels that stimulate libido. Low libido (HSDD) in premenopausal women shows good efficacy and tolerability.
Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had “satisfying sexual events”.In those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of “satisfying sexual events” from 2.7 to 3.7 times a month.The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.
The effectiveness of flibanserin was evaluated in three phase 3 clinical trials. Each of the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and the other for sexual desire. Each of the 3 trials also had a secondary endpoint that measured distress related to sexual desire. All three trials showed that flibanserin produced an increase in the number of SSEs and reduced distress related to sexual desire. The first two trials used an electronic diary to measure sexual desire, and did not find an increase. These two trials also measured sexual desire using the Female Sexual Function index (FSFI) as a secondary endpoint, and an increase was observed using this latter measure. The FSFI was used as the co-primary endpoint for sexual desire in the third trial, and again showed a statistically significant increase.
Contact Person: bruce